home.aspx
 
EVENTS

Annual Psychopharmacology Update
ANNUAL PSYCHOPHARMACOLOGY UPDATE
December 04-05, 2020
Annual Psychopharmacology Update features the world's leading experts who will discuss the latest advances in the pharmacotherapy of anxiety disorders, mood disorders, schizophrenia, and more.

Pharmaceutical Drug Pricing Strategies Summit
PHARMACEUTICAL DRUG PRICING STRATEGIES SUMMIT
December 09-10, 2020
The Pharmaceutical Drug Pricing Strategies Summit is designed to bring senior pricing and reimbursement leaders to discuss the future of federal and state pricing requirements, transparency regulations, and strategic drug pricing models.

Azurity Pharmaceuticals

SHARESHARESHARE
CutisPharma, Inc., based in Wilmington, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.
SHARESHARESHARE

RELATED NEWS


A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge the current clinical guideline that heart-attack survivors should take all three drugs - beta blockers, ACE inhibitors and statins - for the rest of their lives....

READ MORE

While Republican lawmakers in Washington D.C. are falling over each other in a rush to repeal the Affordable Care Act, a.k.a. Obamacare, we think citizens would be better served – in addition to our nation’s health care – if politicians would catch their collective breath if not their senses and cast a critical eye at the pharmaceutical industry....

READ MORE

European regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer....

READ MORE

A new Tel Aviv University study published last month in Oncotarget discloses the role of three proteins in killing fast-duplicating cancer cells while they're dividing. The research, led by Prof....

READ MORE

US-based Dragonfly Therapeutics has announced it has signed a multi-target collaboration with AbbVie to advance immunotherapies created using its Tri-specific Natural Killer (NK) cell engager Therapies (TriNKET) technology for autoimmune and oncology indications. AbbVie has made an undisclosed upfront payment to Dragonfly, and has agreed to future success-based milestone and royalty payments. As a result of the agreement, AbbVie will have the option to license exclusive, global rights to develop...

READ MORE

The FDA has accepted two new antibacterial drug applications from Merck & Co, both of which have received Priority Review. The first application is for the company’s combination of relebactam, an investigational beta-lactamase inhibitor, with imipenem/cilastatin (MK-7655A, IMI/REL), for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by certain susceptible Gram-negative bacteria. In addition, the FDA has accepted a s...

READ MORE

EVENTS

Annual Psychopharmacology Update
ANNUAL PSYCHOPHARMACOLOGY UPDATE
December 04-05, 2020
Annual Psychopharmacology Update features the world's leading experts who will discuss the latest advances in the pharmacotherapy of anxiety disorders, mood disorders, schizophrenia, and more.

Pharmaceutical Drug Pricing Strategies Summit
PHARMACEUTICAL DRUG PRICING STRATEGIES SUMMIT
December 09-10, 2020
The Pharmaceutical Drug Pricing Strategies Summit is designed to bring senior pricing and reimbursement leaders to discuss the future of federal and state pricing requirements, transparency regulations, and strategic drug pricing models.